# Atropa belladonna (Belladonna)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/atropa-belladonna
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-03-25
**Evidence Score:** 2 / 10
**Category:** European
**Also Known As:** Atropa belladonna, Deadly nightshade, Devil's berries, Death cherries, Beautiful death, Dwale, Belladonna alkaloids, Solanaceae nightshade

## Overview

Belladonna (Atropa belladonna) contains tropane alkaloids—primarily atropine and scopolamine—that act as competitive antagonists at muscarinic [acetylcholine](/ingredients/condition/cognitive) receptors, producing anticholinergic effects across smooth muscle, cardiac, and glandular tissues. These compounds have been studied for applications ranging from gastrointestinal spasm relief to cardiac support and pain management.

## Health Benefits

• May help manage acute encephalitis syndrome symptoms (systematic review of 20 studies, n=2302)
• Shows potential for reducing urethral stent pain (systematic review evidence)
• May support cardiac function in myocardial ischemia injury (systematic review evidence)
• Could help with irritable bowel syndrome symptoms (systematic review evidence)
• May provide relief from throbbing headaches (systematic review evidence)

## Mechanism of Action

The primary bioactive alkaloids in Atropa belladonna—atropine (dl-hyoscyamine) and scopolamine (hyoscine)—competitively antagonize muscarinic [acetylcholine](/ingredients/condition/cognitive) receptors (M1–M5 subtypes), blocking parasympathetic nerve transmission at smooth muscle, cardiac sinoatrial nodes, and exocrine glands. Atropine's blockade of cardiac M2 receptors increases heart rate and improves atrioventricular conduction, which underlies its proposed benefit in myocardial ischemia models. Scopolamine's preferential binding to M1 and M3 receptors contributes to antispasmodic and antisecretory effects in gastrointestinal tissue, reducing smooth muscle contractility via inhibition of phospholipase C–mediated intracellular calcium release.

## Clinical Summary

A systematic review encompassing 20 studies (n=2,302) examined belladonna alkaloids in the context of acute encephalitis syndrome symptom management, though evidence quality varied and conclusions require cautious interpretation. Systematic review evidence also supports the use of belladonna-derived alkaloids for reducing urethral stent-related pain, with anticholinergic mechanisms dampening smooth muscle spasms in the urinary tract. Cardiac applications in myocardial ischemia injury have been explored in systematic review-level evidence, suggesting atropine's M2 antagonism may confer cardioprotective benefit, though most underlying studies are preclinical or small-scale. Evidence for irritable bowel syndrome relief is mechanistically plausible given antispasmodic activity, but robust, large-scale randomized controlled trial data specifically for whole-plant belladonna extracts remains limited.

## Nutritional Profile

Atropa belladonna is a medicinal plant, not a food source, and is not consumed for nutritional value due to its high toxicity. Nutritional macronutrient data (carbohydrates, proteins, fats) is not documented for dietary purposes. Key bioactive compounds include: Tropane alkaloids (primary constituents) — atropine (dl-hyoscyamine) at approximately 0.3–0.6% in leaves and 0.4–0.8% in roots (dry weight); l-hyoscyamine (the biologically active enantiomer, comprising the majority of total alkaloid content before racemization); scopolamine (hyoscine) at approximately 0.06–0.3% in leaves; apoatropine and belladonnine as minor alkaloids. Total alkaloid content in leaves ranges from 0.3–1.0% dry weight, with roots containing 0.4–1.3%. Phenolic compounds include chlorogenic acid, caffeic acid, and flavonoids (quercetin, kaempferol glycosides) at trace concentrations (estimated 0.1–0.5% dry weight). Coumarins including scopoletin have been identified. The berries contain solanine-related glycoalkaloids. Carotenoids (including lutein and beta-carotene) are present in minor quantities in the leaves. Bioavailability note: Atropine and hyoscyamine are rapidly absorbed through mucous membranes, skin (transdermal), and the gastrointestinal tract with high systemic bioavailability (~90%); scopolamine crosses the blood-brain barrier readily. All parts of the plant are poisonous — the lethal dose of atropine in adults is estimated at 10 mg, and 2–5 berries may be fatal to children. No conventional vitamins or dietary minerals have been characterized in meaningful concentrations.

## Dosage & Preparation

Clinically studied oral doses include Atropa belladonna tincture (0.1 mg/ml alkaloids) at 1 ml (vagotonic effects), 2 ml (low-moderate), and 5 ml (vagolytic effects), with atropine/scopolamine ratio 20:1. No standardized extract dosages or powder forms were specified in trials. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Belladonna alkaloids carry a narrow therapeutic index; even modest overdoses can cause anticholinergic toxidrome characterized by tachycardia, mydriasis, dry mucous membranes, urinary retention, hyperthermia, and central nervous system agitation or delirium. Belladonna is contraindicated in individuals with angle-closure glaucoma, benign prostatic hyperplasia, myasthenia gravis, and tachyarrhythmias. Significant drug interactions occur with other anticholinergic agents (additive toxicity), antihistamines, tricyclic antidepressants, and monoamine oxidase inhibitors; it may also reduce the absorption of certain oral medications by slowing gastric motility. Belladonna is classified as unsafe during pregnancy due to teratogenic potential of tropane alkaloids and is not recommended during breastfeeding, as atropine is excreted in breast milk and can cause infant toxicity.

## Scientific Research

A systematic review (1965-2020) analyzing 20 studies with 2,302 patients found belladonna safe and effective for multiple conditions using GRADE methodology (PMID: 32662978). One single-blind placebo-controlled RCT (n=8) tested Atropa belladonna tincture showing dose-dependent vagolytic and vagotonic effects (PMID: 11485281). However, no large-scale RCTs or meta-analyses with standardized extracts were identified, limiting evidence to smaller trials.

## Historical & Cultural Context

Belladonna has been used in European folk medicine and traditional systems for centuries to treat gastrointestinal spasms, asthma, bronchitis, jaundice, and motion sickness. Traditional formulations include belladonna-phenobarbital for spasmodic disorders, though historical use has been limited by its toxicity profile.

## Synergistic Combinations

Phenobarbital (traditional combination), physostigmine (as antidote only), activated charcoal (poisoning management), midazolam (toxicity treatment)

## Frequently Asked Questions

### What is belladonna used for in supplements?

Belladonna is used primarily for its anticholinergic alkaloids—atropine and scopolamine—which relax smooth muscle tissue. Supplement and homeopathic applications target gastrointestinal spasms associated with irritable bowel syndrome, urinary tract pain from ureteral stents, and historically, respiratory and cardiac conditions. Most modern therapeutic uses derive from isolated pharmaceutical-grade atropine rather than whole-plant extracts.

### Is belladonna safe to take as a supplement?

Belladonna has a very narrow therapeutic window, meaning the gap between an effective dose and a toxic dose is small. Side effects at higher doses include rapid heart rate, blurred vision, dry mouth, urinary retention, and potentially life-threatening delirium or hyperthermia. Homeopathic preparations are so highly diluted that direct alkaloid toxicity is unlikely, but standardized extract supplements carry genuine risk and should only be used under medical supervision.

### How does belladonna relieve irritable bowel syndrome symptoms?

Belladonna's primary alkaloid, atropine, blocks M3 muscarinic receptors on gastrointestinal smooth muscle cells, inhibiting acetylcholine-driven contractions and reducing intestinal cramping. This antispasmodic action decreases colonic motility and can relieve pain associated with IBS. Some combination antispasmodic preparations containing belladonna alkaloids have been used clinically for IBS, though evidence from large-scale trials specifically using belladonna alone is limited.

### What is the active compound in Atropa belladonna?

The principal bioactive compounds are the tropane alkaloids atropine (dl-hyoscyamine) and scopolamine (hyoscine), with atropine typically predominating. l-Hyoscyamine is the naturally occurring enantiomer and is pharmacologically more potent than racemic atropine at muscarinic receptors. The plant also contains smaller amounts of apoatropine and belladonnine, though these contribute minimally to the primary pharmacological effects.

### Can belladonna interact with prescription medications?

Yes, belladonna alkaloids have clinically significant interactions with multiple drug classes. Combining belladonna with other anticholinergic drugs—such as tricyclic antidepressants, certain antihistamines (e.g., diphenhydramine), or bladder medications like oxybutynin—produces additive anticholinergic toxicity. Belladonna may also slow gastric emptying, reducing the absorption rate of drugs like levodopa, ketoconazole, and iron supplements, and it can antagonize the prokinetic effects of metoclopramide.

### What is the recommended dosage range for belladonna supplements?

Belladonna supplements are typically standardized to contain specific alkaloid concentrations (usually 0.3–0.6% alkaloids) due to the plant's narrow therapeutic window and toxicity risk. Dosing varies by formulation and intended use, ranging from 0.5–2 mg of total alkaloids per dose, but should always follow product labeling and healthcare provider guidance. Because belladonna has a steep dose-response curve, self-dosing without professional oversight is not recommended due to overdose risks.

### Is belladonna safe for children and elderly populations?

Belladonna is generally contraindicated in children due to their increased sensitivity to anticholinergic effects and higher risk of toxicity from accidental overdose. Elderly individuals may also be at greater risk due to age-related changes in drug metabolism and increased susceptibility to anticholinergic side effects such as urinary retention and cognitive impairment. Medical supervision is essential if belladonna is considered for any vulnerable population.

### What does the clinical evidence show about belladonna's effectiveness for different conditions?

Systematic reviews support belladonna's potential role in managing acute encephalitis syndrome symptoms (20 studies, n=2,302) and reducing urethral stent-related pain, with emerging evidence for cardiac function support in myocardial ischemia. However, the overall quality and quantity of rigorous clinical trials remain limited compared to modern pharmaceuticals, and many traditional uses lack robust modern validation. Most clinical evidence comes from observational studies or older literature rather than recent randomized controlled trials, necessitating caution in claims about efficacy.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*